Mode
Text Size
Log in / Sign up

PSMA-targeted radioguided surgery shows high diagnostic accuracy in prostate cancer meta-analysisPSMA guided surgery shows better accuracy for prostate cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider PSMA-RGS as a promising intraoperative tool for nodal staging in prostate cancer, pending confirmatory trials.

This meta-analysis of 28 studies assessed the diagnostic performance of PSMA-targeted radioguided surgery (PSMA-RGS) in patients with prostate cancer. The analysis compared PSMA-RGS with preoperative imaging across patient, lesion, region, and lymph node levels.

Key findings include ex vivo PSMA-RGS specificity up to 100%, in vivo sensitivity of 90-97%, and in vivo specificity of 90-99%. The log diagnostic odds ratio (DOR) for PSMA-RGS was 5.77 versus 2.99 for preoperative imaging (p<0.0001), indicating superior diagnostic accuracy.

Limitations were not reported in the source, and safety data including adverse events were not reported. The authors note that PSMA-RGS demonstrates robust diagnostic accuracy across multiple analytical levels, and intraoperative gamma-probe guidance may enable real-time localization of otherwise undetected nodal metastases, potentially refining intraoperative decision-making.

Practice relevance is tempered by the fact that this is a meta-analysis of observational studies; clinical utility in high-risk surgery is suggested by initial evidence but not proven as a definitive outcome. Further prospective trials are needed to establish impact on oncologic outcomes.

How this fits prior evidence

This meta-analysis extends prior coverage on PSMA-targeting radiotracers by focusing on intraoperative detection rather than imaging alone. Prior findings noted varying liver background SUV between PSMA radiotracers affecting patient selection; this analysis suggests PSMA-RGS may overcome some limitations by enabling real-time localization. It also complements radiomics models predicting biochemical recurrence (sensitivity 0.82) by offering a surgical adjunct for nodal staging. The results do not directly address hypokalemia risks from ARATs or vitamin D associations.

When doctors treat prostate cancer, finding every hidden piece of the disease is a major challenge. Standard preoperative imaging can sometimes miss small areas or lymph nodes where the cancer has spread. This makes it hard for surgeons to know exactly where they need to focus during an operation.

A review of 28 studies looked at PSMA targeted radioguided surgery, which uses a specific protein marker (PSMA) to guide the way. The results showed that this method is much more accurate than standard imaging. It reached sensitivity rates between 90% and 97% and specificity rates between 90% and 99%.

This means the technology helps surgeons see cancer in real time during surgery. While it shows strong promise for finding hidden lymph nodes, it is important to remember that this data comes from a review of existing studies. It suggests the tool is very accurate, but doctors will still use their judgment to decide how to best treat each patient.

What this means for you:
PSMA guided surgery provides higher accuracy than standard imaging for finding prostate cancer and lymph nodes.

Common questions

How accurate is PSMA guided surgery for finding cancer?

The study found that PSMA guided surgery has high accuracy. It showed sensitivity rates between 90% and 97% and specificity rates between 90% and 99%. These numbers suggest it is very effective at identifying the location of prostate cancer compared to standard preoperative imaging.

How does this differ from standard imaging?

Standard preoperative imaging is the usual way doctors see where cancer is before surgery. This study found that PSMA guided surgery performed better than those standard images, with a much higher diagnostic odds ratio of 5.77 compared to 2.99.

Can this help surgeons find lymph nodes?

Yes, the technology can help surgeons find lymph nodes that might be missed by other methods. It allows for real-time location of these areas during surgery, which helps doctors make better decisions about where to focus their efforts.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (PSMA-RGS) is a promising intraoperative technique for improving lesion localization and surgical accuracy in prostate cancer (PCa), particularly in high-risk or recurrent cases. OBJECTIVE: To systematically evaluate the diagnostic performance of PSMA-RGS in PCa using multilevel meta-analysis. METHODS: Following PRISMA 2020 guidelines, we searched PubMed, Embase, and Web of Science for clinical studies published between January 2016 and May 2025, with the final search performed on May 1, 2025, and identified 28 eligible studies. Diagnostic accuracy was assessed at the patient, lesion, region, and lymph node levels, using pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratios (DOR). Random-effects meta-analyses were conducted and risk of bias was evaluated with the ROBINS-I tool. RESULTS: Ex vivo PSMA-RGS demonstrated the highest specificity (up to 100%), while in vivo PSMA-RGS showed excellent sensitivity (90–97%) and specificity (90–99%), particularly at the lymph node level. Across all evaluated anatomical levels, PSMA-RGS consistently outperformed preoperative imaging (log DOR: 5.77 vs. 2.99; p < 0.0001). All diagnostic results were confirmed by histopathology as the reference standard. Meta-regression identified in vivo PSMA-RGS, lymph node–based analysis, and γ-probes combined with high-purity germanium detectors—used for post-resection confirmation—as independent predictors of improved diagnostic performance. CONCLUSION: PSMA-RGS demonstrates robust diagnostic accuracy across multiple analytical levels, including per-patient, per-lesion, and per-node assessments. Initial evidence suggests that intraoperative γ-probes guidance may enable real-time localization of otherwise undetected nodal metastases. In high-risk prostate cancer surgery, this approach may help refine intraoperative decision-making, improve resection completeness, and reduce recurrence.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.